Using risk-based approaches across the product lifecycle to simplify, standardise & enhance the collection of safety data


Dr. Rut explores the product lifecycle and reviews the areas of pharmacovigilance focus and opportunities for improvement for each: • Clinical studies – Maximising intelligence based on limited data • New to market – Establishing safety profile • On Patent Product – License maintenance • Off Patent / OTC – Efficiency and automation

Request Free Demo

Plus get a fixed price pilot — fill in the details below:

For more information contact

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates